Acura Pharmaceuticals, Inc. (ACUR)
| Market Cap | 33.79M |
| Revenue (ttm) | 2.39M |
| Net Income (ttm) | -1.57M |
| Shares Out | 42.89M |
| EPS (ttm) | -0.05 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,500 |
| Open | 0.5401 |
| Previous Close | 0.5500 |
| Day's Range | 0.5000 - 0.5401 |
| 52-Week Range | 0.1500 - 0.7500 |
| Beta | 0.66 |
| Analysts | n/a |
| Price Target | 6.00 (+1,100.0%) |
| Est. Earnings Date | n/a |
About ACUR
Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six add...
Financial Performance
In 2020, ACUR's revenue was $3.57 million, an increase of 34.36% compared to the previous year's $2.66 million. Losses were -$1.21 million, -67.99% less than in 2019.
Financial StatementsNews
Acura Pharmaceuticals Announces Second Quarter 2021 Financial Results
PALATINE, Ill., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR), an innovative drug delivery company engaged in the research, development and commercialization of technologie...
Acura Pharmaceuticals and AD Pharma Amend License to LIMITx™ LTX-03
Amendment Extends NDA Acceptance Date Amendment Extends NDA Acceptance Date